The FDA on Friday approved aficamten (Myqorzo) for symptomatic obstructive hypertrophic cardiomyopathy (HCM), drugmaker Cytokinetics announced. Aficamten is an allosteric and reversible inhibitor of ...
Palo Alto Networks' (PANW) $25 billion purchase of CyberArk (CYBR) and Thoma Bravo's planned $12.3 billion acquisition of Dayforce are among the deals likely to close in the new year. "Thoma Bravo is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback